
Opinion|Videos|April 21, 2025
BPH Management: Patient Outcome Evolution
Author(s)Christopher E. Kelly, MD
Panelist discusses how patient outcomes have evolved over time with different benign prostatic hyperplasia (BPH) treatments, highlighting improvements in ejaculation preservation, durability, and post procedure complications across various techniques.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Evolution of BPH Treatment Outcomes
Dr Christopher Kelly discusses the evolution of patient outcomes with different benign prostatic hyperplasia (BPH) treatments, particularly focusing on ejaculation preservation and durability.
- Early concerns (2010s): He prioritized ejaculation preservation and found UroLift and Rezūm beneficial for this purpose. However, these treatments lacked long-term durability, leading to earlier retreatment needs.
- Transition to modified TURP and GreenLight: To improve durability, he adopted ejaculation-sparing GreenLight laser and transurethral resection of the prostate (TURP). While ejaculation was better preserved, many patients experienced urinary retention due to residual obstructive tissue, sometimes requiring additional surgery.
- Holmium laser experience: Initially, holmium laser procedures resulted in significant urinary incontinence. However, with technique refinement, incontinence decreased, and patients improved with pelvic floor exercises.
- Aqua ablation (2018 onward): Marked a significant improvement in both ejaculation preservation and durability. Patients experienced minimal need for retreatment even after 5 years, an outcome unmatched by prior techniques.
Dr Kelly highlights aqua ablation as the most effective method for maintaining ejaculation while ensuring long-term treatment success.
Advertisement
Related to this article

These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.

Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.

Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Modern BCG outperforms historic benchmarks in high-risk NMIBC
3
Q&A: Gary Kirsh, MD, on health policy for independent urology
4
Suzanne B. Merrill, MD, on the evolving perioperative landscape in MIBC
5

